Anti-TRAIL 抗体 (ab2056)
Key features and details
- Rabbit polyclonal to TRAIL
- Suitable for: IHC-P, WB
- Reacts with: Human
- Isotype: IgG
製品の概要
-
製品名
Anti-TRAIL antibody
TRAIL 一次抗体 製品一覧 -
製品の詳細
Rabbit polyclonal to TRAIL -
由来種
Rabbit -
アプリケーション
適用あり: IHC-P, WBmore details -
種交差性
交差種: Human -
免疫原
Synthetic peptide corresponding to Human TRAIL aa 261-277 (C terminal).
Sequence:CTNEHLIDMDHEASFFGA
(Peptide available asab7867) -
ポジティブ・コントロール
- HeLa whole cell lysate.
-
特記事項
Ligand for DR4 and DR5.The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
バッファー
pH: 7.2
Preservative: 0.02% Sodium azide -
Concentration information loading...
-
精製度
Affinity purified -
ポリ/モノ
ポリクローナル -
アイソタイプ
IgG -
研究分野
関連製品
-
Compatible Secondaries
-
Immunizing Peptide (Blocking)
-
Isotype control
-
Recombinant Protein
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab2056の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
IHC-P |
Use a concentration of 20 µg/ml.
|
|
WB |
1/500. Detects a band of approximately 32 kDa.Can be blocked with TRAIL peptide (ab7867).
Gives a 32 kD band which represents the membrane-bound form of TRAIL. |
特記事項 |
---|
IHC-P
Use a concentration of 20 µg/ml. |
WB
1/500. Detects a band of approximately 32 kDa.Can be blocked with TRAIL peptide (ab7867). Gives a 32 kD band which represents the membrane-bound form of TRAIL. |
ターゲット情報
-
機能
Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG. Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis. -
組織特異性
Widespread; most predominant in spleen, lung and prostate. -
配列類似性
Belongs to the tumor necrosis factor family. -
細胞内局在
Membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 8743 Human
- Omim: 603598 Human
- SwissProt: P50591 Human
- Unigene: 478275 Human
-
別名
- Apo 2 ligand antibody
- APO 2L antibody
- Apo-2 ligand antibody
see all
画像
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) of human brain tissue staining TRAIL with ab2056 at 20µg/ml
-
Western Blot of human brain lysate labeling TRAIL with Anti-TRAIL antibody (ab2056) at (1) 2.5 and (2) 5 µg/ml.
-
Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein including extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein containing extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml.
-
Immunohistochemistry of TRAIL in human brain tissue with TRAIL antibody at 20 µg/ml.
プロトコール
データシートおよび資料
-
Datasheet download
参考文献 (5)
ab2056 は 5 報の論文で使用されています。
- Cutignano A et al. Cytotoxic Potential of the Marine Diatom Thalassiosira rotula: Insights into Bioactivity of 24-Methylene Cholesterol. Mar Drugs 20:N/A (2022). PubMed: 36286419
- Vetsika EK et al. Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients. Cancers (Basel) 13:N/A (2021). PubMed: 33922569
- Melendez ME et al. Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations. Oncotarget 9:27233-27241 (2018). PubMed: 29930761
- Ludwig S et al. Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer. Clin Cancer Res 23:4843-4854 (2017). PubMed: 28400428
- Kawano Y et al. TRAIL produced from multiple myeloma cells is associated with osteolytic markers. Oncol Rep 27:39-44 (2012). PubMed: 21993926